Open Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alpha (PRX-102) 2 mg/kg Administered by Intravenous Infusion Every 4 Weeks in Patients with Fabry Disease
CLI-06657AA1-03
Phase 3 other active
Quick answer
Open Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alpha (PRX-102) 2 mg/kg Administered by Intravenous Infusion Every 4 Weeks in Patients with Fabry Disease for Fabry disease (α-galactosidase A deficiency) is a Phase 3 program (other) at Chiesi Farmaceutici S.p.A with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Chiesi Farmaceutici S.p.A
- Indication
- Fabry disease (α-galactosidase A deficiency)
- Phase
- Phase 3
- Modality
- other
- Status
- active